Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-03-17 Capital/Financing Update
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Share Capital Increase - 17 March 2020 - NL.pdf
Capital/Financing Update Classification · 98% confidence The document announces a capital increase resulting from the exercise of warrants by management and board members. It explicitly details the issuance of new shares, the total capital raised (€5,354,538.80), and updates the total number of voting rights and outstanding warrants, referencing Belgian transparency legislation. This content directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate action related to capital.
2020-03-17 Dutch
6-K Filing
Regulatory Filings
2020-03-17 English
Transformational year for Galapagos
Earnings Release Classification · 98% confidence The document is a press release dated February 20, 2020, presenting financial results and key operational highlights for the full year 2019. It explicitly states: 'Galapagos NV (Euronext & NASDAQ: GLPG) presents financial results and highlights the key events for the full year 2019.' It contains detailed financial tables, management commentary on performance, and an outlook for 2020. This structure is characteristic of an Earnings Release (ER). Although it mentions the upcoming publication of the 'fully audited annual report for the full year 2019' on March 27, 2020, the content provided here is the preliminary announcement of the results, not the comprehensive 10-K filing itself. The document length (43,487 chars) is substantial, suggesting more than just a brief announcement, but its primary function is the release of period results. FY 2019
2020-02-21 Dutch
SC 13G/A Filing
Major Shareholding Notification
2020-02-14 English
SC 13G/A Filing
Major Shareholding Notification
2020-02-14 English
Orphan Drug Designation for GLPG1690 in systemic sclerosis
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV, dated January 29, 2020, announcing that their drug candidate GLPG1690 received Orphan Drug Designation from both the FDA and the European Commission for treating systemic sclerosis (SSc). This type of announcement, detailing a specific regulatory milestone (Orphan Drug Status) and providing updates on clinical trials (Phase 2 NOVESA study), is characteristic of an Earnings Release (ER) or a general regulatory/corporate update. Since it focuses on a specific, positive regulatory event and provides key highlights about the drug development pipeline, it fits best under the 'Earnings Release' category, which often includes significant corporate and pipeline news outside of formal quarterly reports. It is not a full financial report (10-K or IR), a transcript (CT), or a proxy statement (DEF 14A). Given the nature of the announcement (regulatory/pipeline news release), ER is the most appropriate fit among the provided options, as these releases often contain the most timely, high-level corporate news.
2020-01-29 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.